Recent Publications by CFE Educators

PURPOSE

The University of California Preceptor Development Collaborative was established in 2022 across 5 academic medical centers and 3 schools of pharmacy. The collaborative aimed to streamline preceptor development efforts, enhance collaboration, and meet accreditation standards efficiently by providing quarterly preceptor development programming across all sites to residency and school preceptors. This article describes the implementation of the collaborative and assesses the number of attendees, attendee satisfaction, and cost during the pilot year.

SUMMARY

During the pilot year, 5 live virtual preceptor development modules were developed for pharmacist preceptors. There were 631 credit hours claimed (196 from session 1, 106 from session 2, 68 from session 3, 123 from session 4, and 138 from session 5). Preceptor satisfaction, as measured from completed postsession evaluations (n = 704), was high (a median score of 5 on a Likert scale where 1 = none at all, 2 = a little, 3 = a moderate amount, 4 = a lot, and 5 = a great deal) for meeting educational, professional, teaching, or clinical needs. There was strong agreement (median score of 5 on Likert scale where 1 = strongly disagree, 2 = somewhat disagree, 3 = neither agree nor disagree, 4 = somewhat agree, and 5 = strongly agree) that the modules improved knowledge, ability to change practice, and ability to have positive impacts on trainees and patients. The cost per attendee for this series was $1.58 per continuing education credit.

CONCLUSION

A multi-institution state-wide preceptor collaborative effort produced quarterly continuing education for residency and school of pharmacy preceptors who were affiliated with the sites. This approach to preceptor development is a convenient, satisfactory, and cost-effective method to deliver training for pharmacy preceptors.

IntroductionActive cancer and body mass index (BMI) greater than 30 kg/m have been shown to increase venous thromboembolism (VTE) risk in hospitalized patients. Optimal dosing strategies in this population remain uncertain. This study evaluated the incidence of healthcare associated VTE (HA-VTE) in patients with active malignancy and obesity, comparing adjusted versus standard dose enoxaparin for VTE prophylaxis.MethodsThis multicenter, retrospective, cohort study compared enoxaparin 40 mg subcutaneously (SC) daily with adjusted enoxaparin dosing (> 40 mg SC daily) for VTE prophylaxis in hospitalized adult patients with a BMI greater than 30 kg/m who received cancer therapy between January 1, 2020, and August 17, 2023. The primary outcome was incidence of HA-VTE. Secondary outcomes included VTE type and bleeding events. Descriptive statistics were used for all outcomes.ResultsA total of 330 patients were included, with a median BMI of 33.7 kg/m² (IQR 31.6-37.9 kg/m²). Standard dose enoxaparin was administered to 300 patients, while 30 received adjusted doses. HA-VTE occurred in 13 patients in the standard dose group, with no HA-VTE events in the adjusted group (p = 0.245). In the standard dose group, 4 patients had minor bleeds, and 2 had clinically relevant non-major bleeds. One minor bleed occurred in the adjusted group (p = 0.490).ConclusionsHA-VTE was more frequent in the standard dosing group, though the small sample size limits the clinical significance. Patients on adjusted doses did not have increased bleeding events. Further research is needed to determine optimal thromboprophylaxis strategies for cancer patients with a BMI over 30 kg/m².